Spots Global Cancer Trial Database for A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
Official Title: A Phase 1, Open-label, Safety and Pharmacokinetic Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
Study ID: NCT03499444
Conditions
Interventions
Study Description
Brief Summary: This is a Phase 1 open-label, dose-escalation, safety and pharmacokinetic study of rucaparib administered twice daily (BID) to Japanese patients with a solid tumor who have failed previous standard treatment for their cancer. A recommended dose of rucaparib for Japanese patients will be determined in a dose-escalation portion and then further evaluated in a dose-expansion portion of the study.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Division of Medical Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan
Department of Gynecologic Oncology, Saitama Medical Univeristy international Medical Center, Hidaka, Saitama, Japan
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tsukiji, Tokyo, Japan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
